Urinary Tract Pathogen Detection: Reducing Time to Result

Unless otherwise noted, P.A.C.E.™ accreditation will expire six months after the live webinar.

Urinary tract infections (UTIs) are the second most common type of infection and they’re much more common in women than in men. Research suggests that at least 40 to 60 percent of women will develop a UTI during their lifetime, with one in four women likely to have a repeat infection.

Current culture-based methods for detecting UTI pathogens have significant limitations, including subjectivity, long time to result, and missed positive samples. But a molecular alternative that uses real-time PCR technology has the potential to increase the specificity and sensitivity of pathogen detection.

Thermo Fisher Scientific’s new real-time PCR solution for detecting UTI pathogens delivers results in just five hours and increases accuracy by 25% compared to culture-based methods. Verification data has shown that it detected 97% of cases where UTI pathogens were present, while culture methods detected 71% of cases.

Join us in this P.A.C.E.-accredited Fisher Healthcare™ webinar to learn more about this new solution and its potential for improved accuracy and efficiency.

Learning Objectives

This webinar will help you:

• Explain the limitations of culture-based methods and how they can potentially be improved by molecular testing solutions
• Discuss the benefits of detecting urinary tract pathogens using molecular techniques
• Describe how such a solution could be implemented in a laboratory

Watch On Demand      Download Slides (PDF, 3.55MB)

For research use only. Not for diagnostic procedures.

This webinar is produced by Whitehat Communications, a provider of continuing education programs in clinical laboratory sciences that has been approved by the ASCLS P.A.C.E. Program. One P.A.C.E. credit hour will be provided for this complimentary, basic-level program.

David Baunoch, PhD, Pathnostics President and CEO

David Baunoch received his PhD in microbiology and molecular genetics from Wayne State University and completed an NIH Postdoctoral Fellowship in Breast Cancer Research at the Michigan Cancer Foundation. Dr. Baunoch has more than 25 years of laboratory experience in a number of areas and has produced over 25 peer-reviewed publications. Before founding LabPath, he held a variety of executive management positions with industry-leading companies, including Ventana Medical Systems and US LABS, and was founder and president of Combimatrix Molecular Diagnostics.